Tihana Kurtović

Dr. Tihana Kurtović


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Toxins
Verified
Journal Article
Open access
PDF file
EGErika Gamulin
Erika Gamulin
SLSanja Mateljak Lukačević
Sanja Mateljak Lukačević
BHBeata Halassy
Beata Halassy
TKTihana Kurtović
Tihana Kurtović
Envenomations induced by animal bites and stings constitute a significant public health burden. Even though a standardized protocol does not exist, parenterally administered polyclonal antivenoms remain the mainstay in snakebite therapy. There is a prevailing opinion that their application by the i.m. route has poor efficacy and that i.v. administration should preferentially be chosen in order to achieve better accomplishment of the antivenom therapeutic activity. Recently, it has been demonstrated that neutralization not only in the systemic circulation but also in the lymphatic system might be of great importance for the clinical outcome since it represents another relevant body compartment through which the absorption of the venom components occurs. In this review, the present-day and summarized knowledge of the laboratory and clinical findings on the i.v. and i.m. routes of antivenom administration is provided, with a special emphasis on the contribution of the lymphatic system to the process of venom elimination. Until now, antivenom-mediated neutralization has not yet been discussed in the context of the synergistic action of both blood and lymph. A current viewpoint might help to improve the comprehension of the venom/antivenom pharmacokinetics and the optimal approach for drug application. There is a great need for additional dependable, practical, well-designed studies, as well as more practice-related experience reports. As a result, opportunities for resolving long-standing disputes over choosing one therapeutic principle over another might be created, improving the safety and effectiveness of snakebite management.

3 March 2016 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
DSDora Sviben
Dora Sviben
DFDubravko Forčić
Dubravko Forčić
TKTihana Kurtović
Tihana Kurtović
BHBeata Halassy
Beata Halassy
MBMarija Brgles
Marija Brgles

1 August 2021 in Transfusion Clinique et Biologique
Verified
Journal Article
Open access
DRDina Rnjak
Dina Rnjak
SRSanda Ravlić
Sanda Ravlić
AŠA.-M. Šola
A.-M. Šola
BHB. Halassy
B. Halassy
JŠJ. Šemnički
J. Šemnički
MAM. Artuković
M. Artuković
The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunotherapy with convalescent plasma to treat a prolonged, active COVID-19 infection in a patient with a history of nasopharyngeal diffuse large B-cell lymphoma treated with the therapy inducing substantial impairment of particularly humoral arm of immune system. The specific aim was to quantify SARS-CoV2 neutralizing antibodies in a patient plasma during the course of therapy. Besides the standard of care treatment and monitoring, neutralizing antibody titers in patient's serum samples, calibrated according to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human), were quantified in a time-dependent manner. During the immunotherapy period peripheral blood flow cytometry immunophenotyping was conducted to characterize lymphocyte subpopulations. The waves of clinical improvements and worsening coincided with transfused neutralizing antibodies rises and drops in the patient's systemic circulation, proving their contribution in controlling the disease progress. Besides the patient's lack of own humoral immune system, immunophenotyping analysis revealed also the reduced level of helper T-lymphocytes and immune exhaustion of monocytes. Therapeutic approach based on convalescent plasma transfusion transformed a prolonged, active COVID-19 infection into a manageable chronic disease.

17 January 2017 in Clinical Toxicology
Verified
Journal Article
Closed access
MBMiran Brvar
Miran Brvar
TKTihana Kurtović
Tihana Kurtović
DGDamjan Grenc
Damjan Grenc
MBMaja Lang Balija
Maja Lang Balija
Igor KrižajIgor Križaj
Igor Križaj
BHBeata Halassy
Beata Halassy
Context: In clinical practice it is difficult to differentiate between V. berus and V. ammodytes venomous bites. In the past this was not a concern, but due to the current shortage in Viperfav™ and European viper venom antiserum availability, V. a. ammodytes venomous bites have recently been treated with ViperaTAb®, which is a pharmaceutical formulation containing a monospecific ovine Fab fragments against the venom of V. berus. Objective: To evaluate ViperaTAb® in V. a. ammodytes envenomations. Materials and methods: This is a prospective case series of three consecutive patients envenomed by V. a. ammodytes snakebite treated with ViperaTAb®. V. ammodytes venom, neurotoxic ammodytoxins, and Fab fragment levels were determined in serum samples and a pharmacokinetic analysis of the antivenom Fab fragments was carried out. Results: Three patients bitten by V. a. ammodytes with extensive local swelling, neurological symptoms and recurrent thrombocytopenia were treated with ViperaTAb®. V. ammodytes venom was detected in serum of all three patients. Ammodytoxins were detected in the serum of only the most severely envenomed patient who developed neurological symptoms. In the presented moderate cases, a dose of 8 mL of ViperaTAb® reduced swelling and improved systemic effects, such as thrombocytopenia. However, this dose of ViperaTAb® was not effective in the most severely envenomed patient with the highest serum values of V. ammodytes venom. In this case ViperaTAb® did not stop local swelling and it had no effect on neurological signs. ViperaTAb®’s systemic clearance, distribution and elimination half-lives were 4.3–13.4 mL/h/kg, 1.2–3.2 h and 14.1–55.4 h, respectively. Conclusions: In patients envenomed by V. a. ammodytes venom, ViperaTAb® reduces moderate swelling and temporarily improves systemic effects, except neurological symptoms. ViperaTAb® application induces a decrement of V. ammodytes venom level in the blood, but did not affect serum concentration of neurotoxic ammodytoxins in the one patient with measurable concentrations.

1 June 2013 in Biochimie
Verified
Journal Article
Closed access
TSTamara Sajevic
Tamara Sajevic
ALAdrijana Leonardi
Adrijana Leonardi
LKLidija Kovačič
Lidija Kovačič
MLMaja Lang-Balija
Maja Lang-Balija
TKTihana Kurtović
Tihana Kurtović
Igor KrižajIgor Križaj
Igor Križaj

17 June 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TKTihana Kurtović
Tihana Kurtović
MBMaja Lang Balija
Maja Lang Balija
Marija BrglesMarija Brgles
Marija Brgles
DSDora Sviben
Dora Sviben
MTMonika Tunjić
Monika Tunjić
BHBeata Halassy
Beata Halassy
Antivenoms from hyperimmune animal plasma are the only specific pharmaceuticals against snakebites. The improvement of downstream processing strategies is of great interest, not only in terms of purity profile, but also from yield-to-cost perspective and rational use of plasma of animal origin. We report on development of an efficient refinement strategy for F(ab')2-based antivenom preparation. Process design was driven by the imperative to keep the active principle constantly in solution as a precautionary measure to preserve stability of its conformation (precipitation of active principle or its adsorption to chromatographic stationary phase has been completely avoided). IgG was extracted from hyperimmune horse plasma by 2% (V/V) caprylic acid, depleted from traces of precipitating agent and digested by pepsin. Balance between incomplete IgG fraction breakdown, F(ab')2 over-digestion and loss of the active principle's protective efficacy was achieved by adjusting pepsin to substrate ratio at the value of 4:300 (w/w), setting pH to 3.2 and incubation period to 1.5 h. Final polishing was accomplished by a combination of diafiltration and flow-through chromatography. Developed manufacturing strategy gave 100% pure and aggregate-free F(ab')2 preparation, as shown by size-exclusion HPLC and confirmed by MS/MS. The overall yield of 75% or higher compares favorably to others so far reported. This optimised procedure looks also promising for large-scale production of therapeutic antivenoms, since high yield of the active drug and fulfillment of the regulatory demand considering purity was achieved. The recovery of the active substance was precisely determined in each purification step enabling accurate estimation of the process cost-effectiveness. Animal plasma-derived antivenoms constitute the most important therapy against snakebite envenoming. Nowadays this critical treatment has been faced by severe shortage due to low sustainability of current productions, which mostly affects developing countries as those suffering from highest morbidity and mortality rates. Antivenoms' safety and efficacy in clinical setting are highly dependent on manufacturing procedure. Its design should be guided by the tendency to refine immunoglobulin G from residual plasma proteins in only a few easy, simple and efficient purification steps, providing antibody-based product of acceptable physicochemical features and good recovery of protective activity. Here, we developed a compact, feasible and economically viable refinement strategy for antivenom preparation which looks promising for large scale production as well. Process design was driven by the imperative of keeping IgGs or F(ab)2 fragments constantly in solution in order to preserve stability of their conformations. In each of three main steps—caprylic acid precipitation for removal of contaminants, pepsin digestion of IgGs and chromatographic polishing of F(ab')2 active principle, optimal performance conditions were defined. As a result, preparation of completely homogenous and aggregate-free final product with over 75% yield was achieved in the most straightforward way. Also, the novel platform has been supported with process efficiency data, so accurate estimation of the cost-effectiveness is enabled.